Reneo Pharmaceuticals Inc
NASDAQ:RPHM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.1
77.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Reneo Pharmaceuticals Inc
Reneo Pharmaceuticals Inc
Accrued Liabilities
Reneo Pharmaceuticals Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Reneo Pharmaceuticals Inc
NASDAQ:RPHM
|
Accrued Liabilities
$9.5m
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
22%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
25%
|
CAGR 10-Years
24%
|
|
Reneo Pharmaceuticals Inc
Glance View
Reneo Pharmaceuticals Inc. is an innovative biotechnology company focused on developing therapies to address the unmet medical needs of patients suffering from rare, genetic mitochondrial diseases. Founded with a vision to create impactful treatments, Reneo's flagship product, REN001, is currently in clinical trials aimed at restoring energy metabolism in patients with these debilitating conditions. The drug targets the underlying issues within the mitochondria, the powerhouses of the cell, which are often compromised in patients with genetic mitochondrial disorders, leading to diverse and severe health challenges. With a strong pipeline and a commitment to advancing science, Reneo is laying the groundwork to position itself as a pioneer in this specialized and high-demand therapeutic space. For investors, Reneo represents a compelling opportunity at the intersection of cutting-edge science and significant market potential. The company's strategic collaborations and solid financial backing bolster its capacity to navigate the complex development landscape. As the unmet needs of patients with mitochondrial diseases continue to gain recognition, Reneo's focus on innovative solutions places it in a favorable position to capitalize on emerging trends within the biotech industry. Furthermore, the potential for REN001 to become a first-in-class therapy could translate into substantial commercial success, driving long-term value for shareholders and creating a positive impact on the lives of patients. With a competent management team at the helm and promising clinical data on the horizon, Reneo Pharmaceuticals is poised for a significant presence in the biotech market.
See Also
What is Reneo Pharmaceuticals Inc's Accrued Liabilities?
Accrued Liabilities
9.5m
USD
Based on the financial report for Dec 31, 2023, Reneo Pharmaceuticals Inc's Accrued Liabilities amounts to 9.5m USD.
What is Reneo Pharmaceuticals Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
37%
Over the last year, the Accrued Liabilities growth was 82%. The average annual Accrued Liabilities growth rates for Reneo Pharmaceuticals Inc have been 37% over the past three years .
You don't have any saved screeners yet
